Evidence map›Paper›PMID 38980047›Full record

ReviewInfection and immunity2024

The type II secretion system as an underappreciated and understudied mediator of interbacterial antagonism.

Nicholas P Cianciotto

Abstract readReview
In one paragraph

Review in Infection and immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Mucin stimulates the growth ofMicrobiology (Reading, England) · 2026
    Article
  3. Impact of carbapenem-resistantMicrobiology spectrum · 2026
    Article
  4. Article
  5. mBio · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Nicholas P CianciottoDepartment of Microbiology-Immunology, Northwestern University School of Medicine , Chicago, Illinois, USA.ORCID 0000-0002-9572-8322

Funding

Stenotrophomonas maltophilia TfcA and TfcB: Antibacterial T4SS effectors from an emerging human pathogenR21AI171325 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CIANCIOTTO, NICHOLAS P · 2023 to 2024
$420k
Mucinases as Emerging Players in Legionella pneumophila PathogenesisR21AI175460 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CIANCIOTTO, NICHOLAS P · 2023 to 2024
$420k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI171325HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI175460NIAID NIH HHS R21 AI171325NIAID NIH HHS R21 AI175460
6 · The paper itself

Abstract

Interbacterial antagonism involves all major phyla, occurs across the full range of ecological niches, and has great significance for the environment, clinical arena, and agricultural and industrial sectors. Though the earliest insight into interbacterial antagonism traces back to the discovery of antibiotics, a paradigm shift happened when it was learned that protein secretion systems (e.g., types VI and IV secretion systems) deliver toxic "effectors" against competitors. However, a link between interbacterial antagonism and the Gram-negative type II secretion system (T2SS), which exists in many pathogens and environmental species, is not evident in prior reviews on bacterial competition or T2SS function. A current examination of the literature revealed four examples of a T2SS or one of its known substrates having a bactericidal activity against a Gram-positive target or another Gram-negative. When further studied, the T2SS effectors proved to be peptidases that target the peptidoglycan of the competitor. There are also reports of various bacteriolytic enzymes occurring in the culture supernatants of some other Gram-negative species, and a link between these bactericidal activities and T2SS is suggested. Thus, a T2SS can be a mediator of interbacterial antagonism, and it is possible that many T2SSs have antibacterial outputs. Yet, at present, the T2SS remains relatively understudied for its role in interbacterial competition. Arguably, there is a need to analyze the T2SSs of a broader range of species for their role in interbacterial antagonism. Such investigation offers, among other things, a possible pathway toward developing new antimicrobials for treating disease.

Indexed as

Type II Secretion SystemsAnti-Bacterial AgentsAntibiosisBacteriaBacterial ProteinsGram-Negative BacteriaHumansAnti-Bacterial AgentsBacterial ProteinsType II Secretion Systemsantibacterial effectorsbacterial protein secretionbactericidal activitybacteriolytic enzymesinterbacterial competitionT2SStype II secretion

Identifiers

PMID38980047
PMCPMC11320942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.